And that viewpoint re prelinical trials is actually pretty valid in most cases. But RAC is not like most biotechs. I think holders are extremely pumped because holders like @Mason14 are able to situate the preclinical results and contemporary discoveries within RAC's historical performance data in humans - of which there is a lot, to extrapolate the promise of the drug and how future trials may play out.
Meanwhile the market thinks we are "just preclinical" or that we just have an old chemotherapeutic drug.
RAC - Charts & Price Action, page-11887
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.42 |
Change
0.000(0.00%) |
Mkt cap ! $246.3M | |||
| Open | High | Low | Value | Volume |
| $1.43 | $1.45 | $1.40 | $108.3K | 76.53K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 14331 | $1.41 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 11181 | 2 |
View Market Depth
| Last trade - 14.07pm 15/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |